Geover Fernandez, MD
MOHS-Micrographic Surgery · Redondo Beach, CANPI 1639103138
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,774 of the $14,079 with a category attached, or 62.3%. 43 manufacturers reported payments, led by Regeneron at 37.7% of the total. Reporting peaked in 2019 at $6,962 and has fallen 75.8% since, to $1,687 in 2025. Among mohs-micrographic surgery clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 439 payments — averaging $32.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$5K
- AbbVie$2K
- Johnson & Johnson$750
- Amgen$653
- Novartis$551
- Sanofi$486
- plus $4K from 37 others
What the payments were for
- Consulting fees$4,78534%
- Travel & lodging$2792%
- Food & beverage$8,77462%
- Education$2412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,079 in reported general payments places this provider in the 90th percentile of 144 mohs-micrographic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 13 | $47,049 |
| Calcipotriene | 31 | $6,736 |
| Fluorouracil | 66 | $5,218 |
| Doxycycline Hyclate | 135 | $3,489 |
| Fluocinonide | 68 | $2,942 |
| Triamcinolone Acetonide | 89 | $1,345 |
| Ketoconazole | 73 | $1,295 |
| Clindamycin Phosphate | 61 | $1,214 |
| Clobetasol Propionate | 17 | $758 |
| ValacyclovirValacyclovir Hcl | 13 | $649 |
| Betamethasone Dipropionate | 12 | $506 |
| Dapsone | 13 | $460 |
| Mupirocin | 47 | $390 |
| Hydrocortisone | 74 | $321 |
| Cephalexin | 71 | $288 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Redondo Beach
- Sarah ArronBurlingame$98K
- Daniel Zelacla Jolla$43K
- Ralph MasseySanta Monica$38K
- Michael MortazieOrange$29K
- Sumaira AasiStanford$27K
- Andrea WilleySacramento$21K
- Benjamin Kelleyla Jolla$20K
- Frank NoodlemanSaratoga$19K
- Howard FeinRolling Hills Estates$19K
- Joanna ChanLong Beach$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.